Artelo Biosciences (ARTL) vs Bone Biologics (BBLG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Artelo Biosciences is the larger company by market cap ($1.8 million vs $1.3 million), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARTL | BBLG |
|---|---|---|
| Share price | $3.37 | $0.4691 |
| Market cap | $1.85M | $1.29M |
| 1-day change | -1.17% | -3.77% |
| EPS (TTM) | $-136.26 | $-1.37 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $179.19 | $2.76 |
| 52-week low | $3.33 | $0.428 |
| Distance from 52-week high | -98.12% | -83.00% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +2500.72% |
| Average volume | 480.72K | 378.20K |
| Shares outstanding | 547.77K | 2.76M |
| Employees | 7 | 2 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Artelo Biosciences
ARTL stock →Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of cancer-related anorexia; and ART12.11, a cocrystal composition of cannabidiol and tetramethylpyrazine for the treatment anxiety, depression, post-traumatic stress disorder PTSD, epilepsy and insomnia, and other potential indications.
Healthcare · Biotechnology · 7 employees
About Bone Biologics
BBLG stock →Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States. Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which provides target specific control over bone regeneration.
Healthcare · Biotechnology · 2 employees
ARTL vs BBLG FAQ
Which is bigger, Artelo Biosciences or Bone Biologics?
Artelo Biosciences (ARTL) is larger, with a market capitalization of $1.85M compared with $1.29M for Bone Biologics (BBLG).
Are Artelo Biosciences and Bone Biologics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.